Literature DB >> 6734672

Plasma elimination of antithrombin III (heparin cofactor activity) is accelerated in term newborn infants.

B Schmidt, U Wais, W Pringsheim, W Künzer.   

Abstract

Antithrombin III (AT III) levels are markedly increased in newborn infants following exchange transfusion with adult blood, and subsequently return to pre-exchange values. This transient rise in AT III (heparin cofactor activity), was used to estimate its plasma elimination half-life. AT III activities were measured serially, before and after double-volume exchange transfusions with heparinised blood in newborn infants requiring therapy for severe hyperbilirubinaemia. The plasma elimination half-life of AT III activity was calculated to be 3.9 +/- 1.4 h (mean +/- SEM). Compared with published data on the kinetics of AT III infusions in adults, the neonate has a considerably accelerated turnover. This finding has important implications for the design of future therapeutic trials of AT III concentrates and provides further evidence that plasma proteins, including components of the coagulation system, appear to have different kinetics in the neonatal period.

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6734672     DOI: 10.1007/BF00572765

Source DB:  PubMed          Journal:  Eur J Pediatr        ISSN: 0340-6199            Impact factor:   3.183


  9 in total

Review 1.  [Blood coagulation and its disorders in the newborn].

Authors:  W Künzer
Journal:  Klin Wochenschr       Date:  1971-01

2.  Clinical and laboratory diagnosis of hemostatic disorders in newborn infants.

Authors:  A Zipursky; D deSa; E Hsu; M Johnston; R Milner
Journal:  Am J Pediatr Hematol Oncol       Date:  1979

3.  Fibrinogen turnover in the premature infant with and without idiopathic respiratory distress syndrome.

Authors:  D Karitzky; N Kleine; W Pringsheim; W Künzer
Journal:  Acta Paediatr Scand       Date:  1971-07

4.  Substitution therapy with an antithrombin III concentrate in shock and DIC.

Authors:  B Blauhut; S Necek; H Vinazzer; H Bergmann
Journal:  Thromb Res       Date:  1982-08-01       Impact factor: 3.944

5.  Kinetics of elimination of antithrombin III concentrate in heparinized patients.

Authors:  E Marciniak; J P Gockerman
Journal:  Br J Haematol       Date:  1981-08       Impact factor: 6.998

6.  Decreased production or increased turnover of antithrombin III in severe acquired coagulopathy?

Authors:  B Schmidt; U Wais; W Pringsheim; I Witt; W Künzer
Journal:  Klin Wochenschr       Date:  1981-12-15

7.  Biochemical and functional study of antithrombin III in newborn infants.

Authors:  M M McDonald; W E Hathaway; E B Reeve; B D Leonard
Journal:  Thromb Haemost       Date:  1982-02-26       Impact factor: 5.249

8.  Metabolism of antithrombin III (heparin cofactor) in man: effects of venous thrombosis and of heparin administration.

Authors:  D Collen; J Schetz; F de Cock; E Holmer; M Verstraete
Journal:  Eur J Clin Invest       Date:  1977-02       Impact factor: 4.686

9.  Antithrombin III concentrate: its catabolism in health and in antithrombin III deficiency.

Authors:  L Tengborn; B Frohm; L E Nilsson; I M Nilsson
Journal:  Scand J Clin Lab Invest       Date:  1981-09       Impact factor: 1.713

  9 in total
  2 in total

1.  Anticoagulant therapy by continuous heparin-antithrombin III infusion in newborns with disseminated intravascular coagulation.

Authors:  R von Kries; H Stannigel; U Göbel
Journal:  Eur J Pediatr       Date:  1985-07       Impact factor: 3.183

2.  Low antithrombin III in neonatal shock: DIC or non-specific protein depletion?

Authors:  B K Schmidt; T Muraji; A Zipursky
Journal:  Eur J Pediatr       Date:  1986-12       Impact factor: 3.183

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.